Docket No.: 2750-1573PUS1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Nickolai ALEXANDROV

Application No.: 10/572,827 Confirmation No.: 5253

Filed: March 21, 2006 Art Unit: N/A

For: NUCLEOTIDE SEQUENCES AND Examiner: Not Yet Assigned

POLYPEPTIDES ENCONDED THEREBY
USEFUL FOR INCREASING PLANT SIZE
AND INCREASING THE NUMBER AND SIZE

OF LEAVES

INFORMATION DISCLOSURE STATEMENT (SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE 1.114 RCE APPLICATION)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. <u>LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION</u>

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-SB08(s), attached hereto.

II. <u>COPIES</u>

a. Copies of cited U.S. patents and patent application publications are not included.

Copies of foreign patent documents and non-patent literature are included.

Application No.: 10/572,827	Docket No.: 2750-1573PUS1
b. Some or all of the documents list they were cited in the International Search Report	ed on the PTO-SB08 are not enclosed because rt and copies should already be in the PTO file.
If copies are needed, please contact the undersign	ed.
c. <u>REFERENCES PREVIOUSLY CITE</u> §1.98(d), consideration of information listed on patents, publications, or other information which which copies are not enclosed herewith, were pre of the following applications which has been rules. C. § 120:	h are listed on the PTO-SB08 form(s) but for viously cited by or submitted to the PTO in one
III. CONCISE EXPLANATION OF THE RE	<u>LEVANCE</u>
a. <u>DOCUMENTS IN THE ENGLISH LA</u> information listed on the attached PTO SB08 are	NGUAGE - The patents, publications, or other in the English language and therefore, do not
require a statement of relevancy.	
b. <u>DOCUMENTS NOT IN THE ENGLIS</u> relevance of all patents, publications, or other language is as follows:	H LANGUAGE - A concise explanation of the information listed that is not in the English
c. <u>ENGLISH LANGUAGE SEARCH REPO</u> report or action that indicates the degree of relective reports at information and the requirement for a concise expenses.	
d. <u>OTHER</u> - The following additional consideration.	l information is provided for the Examiner's

IV. FEES (check one box) This Information Disclosure Statement is being filed concurrently with the filing a. of a new patent application; therefore, no fee is required. b. This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required. c. This Information Disclosure Statement is being filed within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required. (This section is not to be used with RCE's.) d. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. $\S 1.97(b)(2)$). No fee or statement is required. This Information Disclosure Statement is being filed concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required. \boxtimes f. This Information Disclosure Statement is being filed before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account for the fee as required by 37 C.F.R. § 1.17(p). g. This Information Disclosure Statement is being filed before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)). No statement; therefore, a fee as required by 37 C.F.R. § 1.17(p) is attached.

Application No.: 10/572,827

or

Docket No.: 2750-1573PUS1

Application No.: 10/572,827 Docket No.: 2750-1573PUS1 See the statement below. No fee is required. STATEMENT UNDER 37 C.F.R. § 1.97(e) V. (check only one box) The undersigned hereby states that: X Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or Each item of information contained in the IDS was first cited in any b. communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or No item of information contained in the IDS was cited in a communication from a c. foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS. Some of the items of information were cited in a communication from a foreign d. Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable

VI. <u>PAYMENT OF FEES</u> (check one box)

prior to the filing of this statement.

inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months

Other: